El CRAI romandrà tancat del 24 de desembre de 2025 al 6 de gener de 2026. La validació de documents es reprendrà a partir del 7 de gener de 2026.
El CRAI permanecerá cerrado del 24 de diciembre de 2025 al 6 de enero de 2026. La validación de documentos se reanudará a partir del 7 de enero de 2026.
From 2025-12-24 to 2026-01-06, the CRAI remain closed and the documents will be validated from 2026-01-07.
 
Miniatura

Fitxers

908006.pdf (6.66 MB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2025-12-02

Llicència de publicació

cc-by (c) Kastner, Nina et al., 2025
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/224903

Next-Generation MDMA Analogue SDMA: Pharmacological and Metabolic Insights

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

Resum

3,4-Methylenedioxymethamphetamine (MDMA), commonly known as ecstasy, shows promise in treating depression and post-traumatic stress disorder (PTSD), resulting in breakthrough status. However, concerns regarding MDMA's abuse potential and cytotoxicity have sparked interest in developing safer analogues with similar therapeutic benefits. This study investigated the pharmacological properties of MDMA analogues in which the 1,3-benzodioxole group is replaced by a 1,3-benzoxathiole, termed SDA and SDMA, compared to MDA and MDMA through in silico, in vitro, and in vivo assays. In vitro experiments using human embryonic kidney (HEK293) cells examined the interactions with monoamine transporters. SDA and SDMA showed similar profiles to MDMA at the serotonin transporter (SERT), while both inhibited dopamine (DAT) and norepinephrine (NET) transporters more potently, in line with in silico molecular docking fitness scores of binding. SDA and SDMA also showed increased potency in evoking efflux through SERT and DAT acting as partial releasers. SDA and SDMA exhibited a similar interaction profile with 5-HT2 receptors compared with their respective analogues. Metabolism studies revealed faster clearance rates for SDA and SDMA, in contrast to MDA and MDMA, which exhibited only weak degradation. In contrast to MDMA's rewarding effects, SDMA did not induce significant effects in mice, while SDA only produced a significant preference for the drug-paired compartment at the lowest dose tested. Moreover, while SDMA shares similar locomotor and hyperthermic profiles as MDMA in mice, SDA induced increased hyperlocomotion and more sustained hyperthermia. In conclusion, these findings suggest that SDMA, with enhanced metabolic profiles and reduced abuse potential, is a promising candidate for further studies.

Matèries

Metabolisme dels lípids, Neuropsicofarmacologia, Neurotoxicologia

Matèries (anglès)

Lipid metabolism, Neuropsychopharmacology, Neurotoxicology

Citació

Col·leccions

Articles publicats en revistes (Farmacologia, Toxicologia i Química Terapèutica)

Citació

KASTNER, Nina, NADAL-GRATACÓS, Núria, SHACHAM, Sharon, CUCCURAZZU, Bruna, HALBERSTADT, Adam l., MCCORVY, John d., STOCKNER, Thomas, MEYER, Markus r., LÓPEZ ARNAU, Raúl, GRILL, Matthias, SITTE, Harald h., HEMMER, Selina, ALVES DA SILVA, Leticia, MCKEE, John l., HELL, Tamara, CICALESE, Giulia, HOLY, Marion, KOOTI, Fatemeh, JÄNTSCH, Kathrin, BARON, Roland. Next-Generation MDMA Analogue SDMA: Pharmacological and Metabolic Insights. _ACS Chemical Neuroscience_. 2025. [consulta: 4 de gener de 2026]. ISSN: 1948-7193. [Disponible a: https://hdl.handle.net/2445/224903]

Exportar metadades

JSON - METS

Compartir registre